What’s in vTv Therapeutics Inc (VTVT) After Today’s Big Increase?

September 17, 2017 - By Vivian Currie

The stock of vTv Therapeutics Inc (NASDAQ:VTVT) is a huge mover today! The stock increased 5.96% or $0.32 on September 15, reaching $5.69. About 52,766 shares traded or 88.59% up from the average. vTv Therapeutics Inc (NASDAQ:VTVT) has declined 0.20% since September 17, 2016 and is downtrending. It has underperformed by 16.90% the S&P500.
The move comes after 5 months positive chart setup for the $186.70M company. It was reported on Sep, 17 by Barchart.com. We have $6.15 PT which if reached, will make NASDAQ:VTVT worth $14.94M more.

Analysts await vTv Therapeutics Inc (NASDAQ:VTVT) to report earnings on November, 1. They expect $-0.42 EPS, down 2.44 % or $0.01 from last year’s $-0.41 per share. After $-0.41 actual EPS reported by vTv Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.44 % negative EPS growth.

vTv Therapeutics Inc (NASDAQ:VTVT) Ratings Coverage

Among 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. vTv Therapeutics Inc had 3 analyst reports since August 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 24 by Stifel Nicolaus. Piper Jaffray initiated vTv Therapeutics Inc (NASDAQ:VTVT) on Monday, August 24 with “Overweight” rating. Canaccord Genuity initiated vTv Therapeutics Inc (NASDAQ:VTVT) rating on Friday, September 4. Canaccord Genuity has “Buy” rating and $15 target.

More notable recent vTv Therapeutics Inc (NASDAQ:VTVT) news were published by: Marketwatch.com which released: “5.69” on June 18, 2015, also Businesswire.com with their article: “vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at …” published on June 11, 2017, Bizjournals.com published: “vTv Therapeutics snags funding for study of its diabetes-targeting drug” on September 06, 2017. More interesting news about vTv Therapeutics Inc (NASDAQ:VTVT) were released by: Businesswire.com and their article: “vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST …” published on June 01, 2017 as well as Businesswire.com‘s news article titled: “vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of …” with publication date: September 07, 2017.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $186.70 million. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. It currently has negative earnings. The Company’s drug candidate for the treatment of Alzheimer’s disease is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.